Anavex Life Sciences Corp (AVXL)

[JPG77]

Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

There's a reason as to why Dr. Missling was hired as the CEO - they NEED financing for P2/3, and guess who has the credentials AND CONTACTS to achieve this goal.

There's also a reason as to why he was just given a significant salary increase and millions in options. Let's not forget they've seen much more data (9 months+) than we've seen, and they obviously like what they're seeing, or they wouldn't have rewarded him so well. I can only assume that he was given the significant salary increase and options for a reason, due to his ability to get the additional funding that he's already committed to getting for p2/3. It sounds to me like "things" are progressing as planned. Again, this is just my opinion.